Home Featured Page 201

Featured

Latest

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List...

Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research...

PharmaDrug Announces Initiation of Manufacturing of Cepharanthine (PD-001) For Clinical Programs...

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

Awakn Life Sciences Files Patent Application for a New Class of...

PT287 – Josh Hardman – Psychedelic Stocks, Data Privacy, and Drug...

Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical...

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety...

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in...

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its...

EDITOR PICKS

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.